Journal of Diabetes and Its Complications
Volume 23, Issue 3 , Pages 174-177 , May 2009

Switching from pathogenetic treatment with α-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients

  • Heinz–Jürgen Ruessmann
    • ,
  • on behalf of the German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Ärzte e.V.)

Received 21 June 2007 ,Revised 17 January 2008 ,Accepted 9 February 2008.

References 

  1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. Journal of the American Medical Association. 1998;280:1831–1836
  2. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabetic Medicine. 1993;11:17–21
  3. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clinical Journal of Pain. 2007;23(3):251–258
  4. Boulton AJM, Scarpello JHB, Armstrong WD, Ward JD. The natural history of painful diabetic neuropathy - a 4-year study. Postgraduate Medical Journal. 1983;59:556–559
  5. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. American Journal of Medicine. 2000;108:2–8
  6. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabetic Medicine. 2006;23:1021–1024
  7. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–1522
  8. Flather M, Delahunty N, Collinson J. Generalizing results of randomized trials to clinical practice: Reliability and cautions. Clinical Trials. 2006;3:508–512
  9. Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: Epidemiology, pain description, and quality of life. Diabetes Research and Clinical Practice. 2000;47:123–128
  10. Giannopoulos S, Kosmidou M, Sarmas I, Markoula S, Pelidou SH, Lagos G, et al. Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clinical Journal of Pain. 2007;23:267–269
  11. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clinical Therapeutics. 2006;28:1922–1934
  12. Vera-Llonch M, Dukes E, Delea TE, Wang ST, Oster G Neuropathic Pain Outcomes Modeling Working Group. Treatment of peripheral neuropathic pain: A simulation model. European Journal of Pain. 2006;10:279–285
  13. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Reviews. 2004;25(4):612–628
  14. Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. Journal of Pain. 2006;7:399–407
  15. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic neuropathy. Diabetes Care. 1988;11:34–40
  16. Young MJ, Boulton AJM, Macleod AF, Williams DDR, Sönksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154
  17. Ziegler D. Thioctic acid for patients with symptomatic diabetic neuropathy. A critical review. Treatments in Endocrinology. 2004;3:1–17
  18. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care. 2006;29:2365–2370
  19. Ziegler D, Low PA, Boulton AJM, Vinik AI, Freeman R, Samigullin R, et al. Effect of 4-year antioxidant treatment with a-lipoic acid in diabetic polyneuropathy: The NATHAN 1 trial. Diabetes. 2007;56(suppl):(abstract, in press)
  20. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: A meta-analysis. Diabetic Medicine. 2004;21:114–121

PII: S1056-8727(08)00024-X

doi: 10.1016/j.jdiacomp.2008.02.002

Journal of Diabetes and Its Complications
Volume 23, Issue 3 , Pages 174-177 , May 2009

Article Tools